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INTRODUCTION 
As anarchic cellular proliferation, cancer ranges 
amongst the leading causes of mortality worldwide. Che-
motherapy, radiotherapy, surgery, immunotherapy and 
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electrochemotherapy are the main established anticancer 
therapeutic remedies that can be used in combination and 
according to the cancer type and stage of disease [1,2].
Chemotherapy as a pillar to anti-cancer therapeutic pro-
tocols destroys and impedes cell proliferation. Additionally, 
chemotherapy is known to block cancer cell mitotic cycles 
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Aim. Chemo-herbal combinations promise new clinical anticancer therapeutic modalities. 
The current study investigated and compared the in vitro effects of a bromelain-based 
chemo-herbal combination to/with cisplatin or 5-FU, with regard to the proliferation and 
apoptosis of human gastric AGS and breast MCF7 cell lines.
Material and methods. AGS and MCF7 cells were either treated with different 
concentrations of bromelain, cisplatin or 5-FU; or with bromelain-cisplatin and 
bromelain-5-FU combinations for 48h. Cell proliferative inhibition and inductive apop-
tosis were appraised using MTT assay and flowcytometry, respectively. Kruskal-Wallis  
and Dunn’s tests were used to analyze differences in cell groups’ means.
Results. AGS proliferation was adversely affected by single treatments of bromelain and 
cisplatin (p <0.003) or 5-FU (p <0.05). The anti-proliferative impact of single treatments 
was more pronounced on MCF7 cells. The bromelain-cisplatin combinations displayed 
synergistic effect on MCF7 cells (CIs ≤1), while being additive or antagonistic with 
cisplatin IC30 and IC40 to AGS cell proliferation, respectively. In addition, bromelian-5-FU 
combinations showed synergistic effect on AGS cells, while antagonistic to MCF7 cells. 
In terms of cell apoptosis induction, bromelain (IC30)-cisplatin (IC20) displayed additive 
effect on MCF7, compared to cisplatin single treatment (p <0.04), while bromelain (IC40)-
5-FU (IC10) and bromelain (IC30)-5-FU (IC20) afforded additive apoptotic effects on AGS 
(p <0.04) and MCF7 (p <0.05), respectively, in comparison to 5-FU single treatment.
Conclusion. A bromelain-based combination using cisplatin showed concordant effects 
on cell proliferation impediment and apoptotic induction on MCF7, while the same 
results were noticed with a bromelain-5-FU combination to AGS cells. The bromelain-
based chemo-herbal pathways should further be investigated in the frame of multi-
chemotherapeutic drugs researches.
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as to engender vulnerability when exposed to adjuvant thera-
pies such as radiotherapy [2,3].
Cisplatin (cis-diamminedichloroplatinum (II) or CISPLA-
TIN) sits in the anti-cancer therapeutic armamentarium as 
one of most resorted chemotherapeutic drug in the setting 
of different solid neoplasms (ovarian, testicular, stomach, 
prostate, breast, neck and head, cervix, small-cell and non-
small-cell lung cancer) [4]. Two major clinical concerns 
with cisplatin consist of primary tumor resistance and drug 
side-effects [5]. Exhibited drug resistance by certain neo-
plasms, emerging after initial clinical response, further 
clouds cisplatin anticancer efficacy. The prevalent cispla-
tin side effects include nephrotoxicity, myelosuppression, 
ototoxicity, anaphylactic reactions, peripheral neuropathies 
and hypomagnesaemia. 5-Fluorouracil (5-FU) is one of the 
widely used chemotherapy drugs (especially in breast and 
prostatic cancers). The main therapeutic side-effects of 5-FU 
are nausea, vomiting, mucositis, stomatitis, and diarrhea [6]. 
Overcoming tumor and drug resistance in parallel with 
attempts to undermine clinical side-effects of chemothera-
peutic agents has motivated researches on chemo-herbal 
combinations. Chemo-herbal combinations also increase 
the effectiveness of chemotherapeutic drugs, while lessening 
their toxicity [7]. Aqueous extract of pineapple (bromelain), 
widely used in certain traditional medicine (South America 
and Asia), has shown permissive effects in many physi-
ological and pathophysiological processes such as diges-
tion, wound healing, burnt debris, and optimizing antibiotic 
absorption. Immunomodulatory, anti-inflammatory and anti-
cancer properties were reported as being within the range 
of bromelain therapeutic effects. Indeed, in vitro anticancer 
effects of bromelain were reported in the case of differ-
ent human cancer cells [8]. This study was conducted as to 
investigate the in-vitro impact of bromelain on prolifera-
tive and apoptotic aptitude to two different human cancer 
cells, gastric carcinoma (AGS) and breast adenocarcinoma 
(MCF7) cells in the frame of chemo-herbal combination 
treatment with either cisplatin or 5-FU. 
MATERIALS AND METHODS
Procurement of human cancer cells
Human gastric carcinoma (AGS) and human breast 
adenocarcinoma (MCF7) cell lines were sourced from the 
Pasteur Institute (Tehran, Iran). 
Cell culture
Roswell Park Memorial Institute (RPMI) -1640 supple-
mented with fetal bovine serum (FBS) at 10% volume con-
centration and penicillin/streptomycin 1% volume concen-
tration (Life Technologies, California, USA) was used as 
cell culture medium. Trypsin/EDTA (Life Technologies) 
was applied to enable cell detachment. Cells were counted 
and seeded in new flasks following recommended standard 
protocols (RSP) consisting of maintaining 98% humidity, 
a temperature of 37°C, and a CO2 partial pressure of 5%.
Preparation of stock solutions
Bromelain and cisplatin were purchased from Merck 
(Merck CO., Darmstadt, Germany), and 5-FU was sourced 
from Haupt Pharma (Wolfratshausen GmbH Co, Germany). 
The bromelain, cisplatin, and 5-FU stock solutions were 
prepared using dilution with RPMI-1640 as to obtain respec-
tive concentrations of 30 μM, 250 μM, and 30 μM. Stock 
solutions were kept at 4°C and protected from the light. The 
different target concentrations were obtained by subsequent 
dilution with RPMI-1640.
MTT assay 
The bromelain, cisplatin, and 5-FU inhibitory effect 
on AGS and MCF7 cells proliferation was assessed using 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay [9]. In brief, 10 μL of MTT solution at a con-
centration of 5 mg/ml (Life Technologies, California, USA) 
was added to each well that was incubated for 4 hours. After 
dissolving cells in 200 μL of dimethyl sulfoxide (DMSO) 
(Merck, Darmstadt, Germany) and having incubated for 20 
min, the optical density (OD) of each well was measured 
using a microplate reader (Stat Fax-2100, Awarness Inc., 
Florida, USA) on the light wave-length range of 490-570 
nm. The percentage of cancer cells was assessed based on 
the absorbance of treated cells, as opposed to the untreated 
control cells (viability = A (sample)/A (control) × 100) [9]. 
Annexin V-PI staining to apoptosis assay
AGS and MCF7 cells were seeded in 6-well plates 
(2×105/well) and incubated for 24 hours. Consequently, the 
incubated cells were treated as to reach 75% cells conflu-
ence, either singly with bromelain, cisplatin, and 5-FU; or 
with the two chemo-herbal combination types (bromelain-
cisplatin and bromelain 5-FU). The wells were kept incu-
bated for the following 48h under RSP. The treated cells, 
dead or viable, were collected by trypsination, washed with 
PBS that incorporated the stain, annexin V (BD Bioscience 
California, USA) at the ambient temperature for 35 min. 
Cell analyzing was performed by flowcytometry (CYFLOW 
space, Patrick, Germany) in observance to manufacture’s 
operational guidelines.
Single treatment
Each well of a 96-well plate was filled with 5×103 cells 
per 200 μL issued from the prepared AGS and MCF7 cells 
culture medium. Following an overnight incubation under 
RSP, each well was singly treated with different target con-
centrations of bromelain in the range of 0, 0.5, 1, 2, 3.5, 7, 
14, and 28 μM [10], cisplatin in the range of 0, 0.1, 1, 5, 10, 
20, 40, 50, and 100 μM [10], and 5-FU in the range of 0, 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 μM [9]. Then, wells were kept 
incubated at RSP for 48h. A control well was confined to 
each singled treatment. The experiment for each single treat-
ment was repeated 3 times as three independent experiments 
as to MTT assay and annexin V-PI staining. Cell viability 
percentage was plotted against different concentrations of 
bromelain, cisplatin, or 5-FU. Then, regression probit was 
used to calculate inhibitory concentration of bromelain, 
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cisplatin, and 5-FU corresponding to 10, 20, 30, 40 and 
50% of cancer cell viability (IC10, IC20, IC30, IC40 and IC50).
Chemo-herbal combinational treatment
Having determined ICs by single treatments, wells incor-
porating AGS or MCF7 were treated with four different 
chemo-herbal combinations targeting an additive combina-
tional IC50 of either bromelain-cisplatin (IC10 bromelain plus 
IC40 cisplatin, IC20 bromelain plus IC30 cisplatin, IC30 bro-
melain plus IC20 cisplatin and IC40 bromelain plus IC10 cis-
platin); or bromelain-5-FU (IC10 bromelain plus IC40 5-FU, 
IC20 bromelain plus IC30 5-FU, IC30 bromelain plus IC20 5-FU 
and IC40 bromelain plus IC10 5-FU). Then, wells were kept 
incubated at RSP for 48h. A control well was confined to 
each chemo-herbal combination type. The experiment for 
each chemo-herbal combination type was repeated 3 times in 
three independent experiments. CI values were measured by 
applying CompuSyn software (Combo SynInc, City, State, 
USA). Combination index (CI) values indicated synergistic 
(CI <1), additive effect (CI =1) or antagonism (CI >1).
Data processing
Data were collected and inputted into SPSS 20 statis-
tical software (SPSS, Chicago, IL, USA) and Graph Pad 
Prism 6 (GraphPad Software Inc., San. Diego, CA, USA). 
Results are presented as the percentage of cell viability after 
treating with different concentrations of bromelain, cisplatin, 
or 5-FU (Cell viability % = OD of treated groups/OD of 
untreated groups)[9]. Kruskal-Wallis and Dunn’s tests were 
used to analyze differences in cell group means. A level of 
p-value <0.05 was considered significant.
RESULTS 
Inhibitory effect on cell proliferation
Single treatments
Single treatment on AGS cells
AGS cell viability was significantly decreased in respect 
to single treatment with bromelain (p <0.003), cisplatin 
(p<0.003) and 5-FU (p<0.003), when compared to the 
control in a dose-dependent manner (Fig. 1 A-C). Differ-
ent levels of IC were estimated accordingly (Tab. 1). IC50 
was obtained as 1.2 μM, 6 μM, and 40 μM with regard 
to bromelain, cisplatin and 5-FU, respectively. The inhibi-
tory effect on AGS cells with bromelain showed a similar 
pattern to that displayed by cisplatin (Fig. 1 A-B). 
Single treatment on MCF7 cells
Significant inhibitory effect on MCF7 proliferation was 
detected for the complete range of concentration to brome-
lain (p <0.007), cisplatin (p <0.003) and 5-FU (p <0.007) 
in a dose dependent manner (Fig. 1 D-F), with bromelain 
displaying the most noticeable impact at lower range of con-
centrations. Different levels of ICs were estimated accord-
ingly (Tab. 1). IC50 was obtained as 0.17 μM, 11 μM, and 
9 μM to bromelain, cisplatin and 5-FU, respectively.
Table 1. The viability percentage, the value of CI (combination 
index) and DRI (dose reduction index) of AGS and MCF7 cell 
lines treated with combination of bromelain and cisplatin after 
48h incubation. CI <1: synergistic effect, CI = 1: additive effects 
and CI >1: antagonistic effect
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AGS
No. 1
0.25 μM 
(IC10)
3.4 μM 
(IC40)
83±4.89 4.52 1.62 0.25
No. 2
0.5 μM 
(IC20)
2 μM 
(IC30)
59±4.08 1.01 2.07 1.8
No. 3
0.7 μM 
(IC30)
1.26 μM 
(IC20)
41±2.6 0.52 2.59 6.99
No. 4
1 μΜ 
(IC40)
0.4 μM 
(IC10)
46±3.2 0.70 1.5 17.2
MCF7
No. 1
0.04 μM 
(IC10)
4.36 μM 
(IC40)
22±1.2 0.12 11.96 22.06
No. 2
0.09 μM 
(IC20)
1.77 μM 
(IC30)
28±3.5 0.26 4.24 29.74
No. 3
0.11 μM 
(IC30)
0.63 μM 
(IC20)
21±6.74 0.22 4.53 170.7
No. 4
0.13 μM 
(IC40)
0.15 μM 
(IC10)
41±2.4 0.51 1.9 118.04
Chemo-herbal combinational treatment on AGS and 
MCF 7 cell viability
Bromelain-cisplatin combinational treatment on AGS cells
AGS cells were treated with 4 different brome-
lain-cisplatin concentrations targeting an additive 
IC50 (Tab. 1). Cell viability was significantly 
lessened in all 4 different combined concentrations 
(Tab. 1). Combination index (CI) was measured for 
each of 4 combined concentrations. The reported 
combined concentrations number 3 and 4 resulted 
in CI less than one, indicating a synergistic effect, 
while a CI of more than one was obtained with 
combined concentrations number 1 and 2 which 
reflected an additive and antagonistic effects, 
respectively.
Bromelain- 5-FU combinational treatment on AGS 
cells
AGS cells were treated with 4 different 
combined concentrations of bromelain-5-FU 
targeting an additive IC50 (Tab. 2). Cell viabil-
ity was significantly lessened in all 4 different 
Data are presented as means ± SD of at least three independent experiments
Figure 1. Changes in the percentage of cell viability in AGS cells (a-c), 
and MCF7 cells (d-f) after treatment with different concentrations of 
bromelain (a, d), cisplatin (b, e), and 5-FU (c, f)
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combined concentrations (Tab. 2). When CI was measured 
for each of 4 combined concentrations, the 4 combined 
concentrations resulted in CI less than one, indicating 
a synergistic effect.
Table 2. The viability percentage, the value of CI (combination 
index) and DRI (dose reduction index) of AGS and MCF7 cell 
lines treated with combination of bromelain and 5-FU after 48h 
incubation. CI < 1: synergistic effect, CI = 1: additive effects and 
CI >1: antagonistic effect
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AGS
No. 1
0.25 μM 
(IC10)
30 μM 
(IC40)
26±15 0.30 12.26 4.43
No. 2
0.5 μM 
(IC20)
20 μM 
(IC30)
18±2.8 0.20 8.79 10.78
No. 3
0.7 μM 
(IC30)
10 μM 
(IC20)
14±1.6 0.16 7.9 29.3
No. 4
1 μM 
(IC40)
5 μM 
(IC10)
9±1.92 0.13 8.1 97.7
MCF7
No. 1
0.04 μM 
(IC10)
4.46 μM 
(IC40)
92±0.98 16.5 0.89 0.06
No. 2
0.09 μM 
(IC20)
2.39 μM 
(IC30)
87±1.5 5.7 0.57 0.24
No. 3
0.11 μM 
(IC30)
1.14 μM 
(IC20)
84±2.12 3.1 0.56 0.72
No. 4
0.13 μM 
(IC40)
0.41 μM 
(IC10)
97±2.83 13.11 0.13 0.17
Bromelain - Cisplatin combinational treatment  
on MCF7 cells
MCF7 cells were treated with 4 different 
combined concentrations of bromelain-cisplatin tar-
geting an additive IC50 (Tab. 1). Cell viability was 
significantly lessened in all 4 different combined 
concentrations (Tab. 1). When CI was measured for 
each of 4 combined concentrations, the 4 combined 
concentrations resulted in CI less than one, indicat-
ing a synergistic effect.
Bromelain - 5-FU combinational treatment  
on MCF7 cells
All four tested combined concentrations target-
ing an additive IC50 did not result in any significant 
inhibitory effect on MCF7 cell viability (Tab. 2). 
Attendant calculated CIs displayed an antagonistic 
effect with 4 combinational concentrations (CI >1).
Effect of chemo-herbal combinational 
treatment on cell apoptosis induction
Bromelain - Cisplatin combinational treatment  
on AGS cells
AGS cells were treated with single bromelain 
(IC30), cisplatin (IC20), or their combination with an 
additive IC50 (Fig. 2). The bromelain (IC30)-cispla-
tin (IC20) combination did not result in any additive 
apoptotic effect on AGS cells when compared to 
single treatments with bromelain (IC30) or cisplatin 
(IC20) (p >0.3) (Fig. 2).
Bromelain - 5-FU combinational treatment on AGS cells
AGS cells were treated with single bromelain (IC40), 
5-FU (IC10), or their combination with an additive IC50 
(Fig. 3A-B). Herein, significant additive apoptotic effect on 
AGS cells was detected using bromelain (IC40) 5-FU (IC10) 
when compared to single 5-FU (IC10) treatment (p <0.04). 
No additive apoptotic effect was detected in comparison to 
single bromelain (IC40); (p <0.3) (Fig. 3B).
Bromelain - Cisplatin combinational treatment on MCF7 
cells
MCF7 cells were treated with either single bromelain 
(IC30), Cisplatin (IC20), or their combination with an additive 
IC50 (Fig. 4A-B). Significant additive apoptotic effect on 
MCF7 cells was detected using bromelain (IC30)-cisplatin 
(IC10) combination, when compared to single cisplatin 
(IC20) treatment (p<0.04). No additive apoptotic effect was 
detected in comparison to single bromelain (IC30); (p >0.3). 
Bromelain - 5-FU combinational treatment on MCF7 cells
MCF7 cells were treated with either single bromelain 
(IC30), 5-FU (IC20), or their combination with an additive 
IC50 (Fig. 5 A-B). Significant additive apoptotic effect on 
MCF7 cells was detected using bromelain (IC30)-5-FU (IC20) 
when compared to single 5-FU (IC20) treatment (p<0.05). 
No additive apoptotic effect was detected in comparison to 
single bromelain (IC30); (p >0.3) (Fig. 5).
All data were expressed as the mean ± SD
Figure 2. Bromelain and cisplatin effect on the apoptosis of AGS. (A) Dot-
plots from flowcytometric illustrating apoptotic status in AGS cells. (B) Total 
percentage of apoptosis in AGS cells treated with the indicated concentrations 
of bromelain (0.7 μM) and cisplatin (1.26 μM) or a combination of bromelain 
with cisplatin (0.7 μM and 1.26 μM, respectively) for 48h
All data were expressed as the mean ± SD
Figure 3. Bromelain and 5-FU effect on the apoptosis of AGS. (A) Dot-plots 
from flowcytometric illustrating apoptotic status in AGS cells. (B) Total 
percentage of apoptosis in AGS cells treated with the indicated concentrations 
of bromelain (1 μM) and 5-FU (5 μM) or a combination of bromelain with 
5-FU (1 μM and 5 μM, respectively) for 48h
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DISCUSSION
Anticancer therapy has evolved from a pure chemico-
physical approach towards gaining advantages in the 
ongoing insight of multi-modal disease management. 
Currently, chemotherapy as a pillar to anticancer therapy, 
carries drug side-effects and tumor resistance as two major 
clinical realms. Cisplatin (cis-diamminedichloroplatinum 
(II) or cisplatin) and 5-FU (5-fluorouracil) are two major 
chemotherapeutic drugs that are widely integrated in anti-
cancer protocols [4]. Cisplatin’s mode of action is based 
on hidden DNA repair mechanisms (crosslinking with the 
purine bases); thereby damaging DNA and inducing cancer 
cell death. By replacing thymine in the DNA or uracil in 
RNA, 5-FU acts as antimetabolite leading to cancer cell 
apoptosis induction [6].
As part of continuous efforts to overcome chemother-
apy clinical limitations, enhance its therapeutic impact, 
and ameliorate attendant clinical tolerance, chemo-herbal 
combinations have emerged as promising investigational 
ways to explore. By coupling the properties of natural 
herbal products to classical chemotherapeutic drugs, chemo-
herbal combination does synergistically boost the anticancer 
radius of chemotherapy that may lead towards reducing the 
required doses of chemical drugs [7].
Bromelain, the core component of the pineapple, 
is noted for having anti-inflammatory and antican-
cer properties that deserved scientific interest and 
focus. Immunomodulation, anti-fibrinolysis, and 
proteolysis represent other bromelain reported 
clinic benefits. The in vitro influence of brome-
lain on various human cancer cells was reported 
[8]. Increasing expression of p53 and Bax genes 
involved in apoptosis induction, and inhibiting the 
anti-apoptotic regulator genes (such as Akt/Erk 
genes) were acknowledged as bromelain anticancer 
modes of action. Certain radio-sensitizing proper-
ties of bromelain in murine breast cancer 4T1-cells 
were also demonstrated [11].
Given the reported anticancer potential, research 
was oriented towards chemo-herbal combinations 
that include bromelain. The synergistic impact of 
bromelain was investigated with N-acetylcysteine 
on gastrointestinal cancer cells [12,13], cisplatin 
on MDA-MB-231 human breast cancer cells [9], 
papain on human cholangiocarcinoma cells [14], 
as well as with cisplatin or 5-FU on malignant peri-
toneal mesothelioma [15].
Mirroring the advocated anticancer properties of 
bromelain, the current study aimed at investigating 
its impact in combination with chemotherapeutic 
drugs on cancer cell viability inhibition, as well 
apoptosis induction. Inhibition to cell viability 
resulted in the frame of single treatment with bro-
melain on AGS showing a pattern similar to that 
displayed by cisplatin (Fig. 1A-B). When it came 
to MCF7, cisplatin displayed the same pattern of 
cell viability inhibitory effect, though with a higher 
IC50 (11 µm) when compared to the IC50 (6 µm) 
obtained on AGS. In contrast, bromelain and 5-FU 
showed higher potency on MCF7 at a lower range of con-
centrations, as witnessed by their respective IC50 of 0.17 
and 9 µM (Fig. 1D-F).
The bromelain-cisplatin effect on AGS cell viability 
inhibition also showed an additive impact with combined 
concentrations number 2 (Tab. 1), while combined concen-
trations number 3 and 4 revealed synergistic effects (Tab. 1). 
A synergistic effect on MCF7 was noticed with the all four 
different bromelain-cisplatin combined concentrations, advo-
cating a higher in-vitro efficacy of the latter chemo-herbal 
combinational treatment on MCF7, when compared to that 
observed with AGS cells (Tab. 1). The latter was in contrast 
with the bromelain-5-FU chemo-herbal combination, where 
all the four different combined concentrations displayed syn-
ergistic effects on AGS; while being antagonistic on MCF7 
with all 4 different combined concentrations (Tab. 2).
The chemo-herbal combination of bromelain-cisplatin 
on AGS apoptotic induction displayed no additive effects, 
in comparison to the respective single treatment either with 
bromelain or cisplatin (Fig. 2). In contrast, bromelain-5-FU 
chemo-herbal treatment demonstrated an additive effect on 
AGS cell apoptotic induction when compared to control and 
5-FU (Fig. 3). The chemo-herbal combination of brome-
lain- cisplatin also revealed an additive effect on MCF7 cell 
apoptotic induction, compared to control and single cisplatin 
All data were expressed as the mean ± SD
Figure 4. Bromelain and cisplatin effect on the apoptosis of MCF7. (A) 
Dot-plots from flowcytometric illustrating apoptotic status in MCF7 cells. 
(B) Total percentage of apoptosis in MCF7 cells treated with the indicated 
concentrations of bromelain (0.11 μM) and cisplatin (0.63 μM) or a 
combination of bromelain with cisplatin (0.11 μM and 0.63 μM, respectively) 
for 48h
All data were expressed as the mean ± SD
Figure 5. Bromelain and 5-FU effect on the apoptosis of MCF7. (A) Dot-
plots from flowcytometric illustrating apoptotic status in 5-FU cells. (B) 
Total percentage of apoptosis in MCF7 cells treated with the indicated 
concentrations of bromelain (0.11 μM) and 5-FU (1.14 μM) or a combination 
of bromelain with 5-FU (0.11 μM and 1.14 μM, respectively) for 48h
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treatment (Fig. 4). Moreover, the bromelain-5-FU combina-
tion exerted additive effect on MCF7 cell apoptotic induc-
tion, in comparison to the 5-FU single treatment (Fig. 5). 
These findings sustained the potent bromelain anticancer 
effect that can be taken advantageously in enhancing the 
effect of cisplatin and 5-FU chemotherapeutic drugs.
The driver synergistic or additive role of bromelain in 
combination with chemotherapeutic drugs was reported in a 
few previous studies. Pillai et al. demonstrated that chemo-
herbal bromelain-cisplatin exerted a significant enhanced 
cytotoxic effect on PET and YOU cells (malignant peri-
toneal mesothelioma), when compared to cisplatin alone 
[15]. Similarly, Pauzi et al. reported the in vitro synergistic 
enhancing effect of bromelain in combination with cisplatin 
on MDA-MB-231 breast cancer cells in respect to apop-
totic induction [9]. The latter paralleled the observed current 
findings of the synergistic or additive effect of bromelain-
based chemo-herbal combinations on AGS and MCF7 with 
regard to inhibiting cell viability and apoptotic induction 
processes. Nevertheless, Pillai et al. did not report any anti-
cancer enhancement using bromelain-5-FU combination on 
PET and YOU cells [15].
In the current study, the latter chemo-herbal combina-
tion displayed synergistic anticancer effects on AGS cells, 
but demonstrated an antagonist effect on MCF7 cell via-
bility inhibition. The synergistic effect of bromelain was 
also highlighted in association with N-acetylcysteine on a 
panel of gastrointestinal cancer cells in terms of increasing 
cytotoxicity, cytophagy and cell apoptotic induction [12]. 
Compounding the previous reported anticancer effects of 
bromelain-based chemo-herbal combination in conjunction 
with the current findings emphasizes the potential benefits of 
bromelain in future anticancer multi-modal therapy.
CONCLUSIONS
Bromelain is innately dotted with in vitro inhibitory prop-
erties on human PC3 and MCF7 cell viability, as well as 
in the induction of cell apoptosis. In our work, we demon-
strated that bromelain-based chemo-herbal combination with 
cisplatin or 5-FU produced various effects on cell viability 
and apoptosis in AGS or MCF7 cell lines that are positive 
in terms of anticancer treatment. In addition, current and 
previous research has revealed that bromelain-based chemo-
herbal combinations do yield to clinical perspectives as to 
lessen chemotherapeutic clinical limitations, while sub-
stantially boosting their anticancer radius of action. Never-
theless, it is inventively advised that bromelain anticancer 
effects be further investigated on the basis of multi- chemo-
therapeutic drug protocols.
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